Literature DB >> 25560489

p21-Activated kinase 5 affects cisplatin-induced apoptosis and proliferation in hepatocellular carcinoma cells.

Ding-Guo Zhang1, Jinling Zhang, Lin-Lin Mao, Jin-Xia Wu, Wen-Jia Cao, Jun-Nian Zheng, Dong-Sheng Pei.   

Abstract

p21-Activated kinase 5 (PAK5) is the last identified member of the PAK family. The PAKs are highly conserved serine/threonine and effector proteins for Cdc42 and Rac and are essential in regulating cell motility and survival. Previous studies have demonstrated that PAK5 played a pivotal role in apoptosis, proliferation, cancer migration, and invasion. However, the biological function of PAK5 in hepatocellular carcinoma, as well as its underlying mechanism, still remains to be fully elucidated. In the present study, we demonstrated that PAK5 markedly inhibited cisplatin-induced apoptosis and promoted cell proliferation in hepatocellular carcinoma cells. Moreover, our results showed that overexpression of PAK5 contributed to cell cycle regulation. In order to elucidate the underlying mechanism of PAK5 on cisplatin-induced apoptosis and cell cycle regulation, we also examined the protein expressions of chk2 and p-chk2. In summary, our study investigated the role of PAK5 in cisplatin-induced cellular processes and provided evidence of its underlying mechanism.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25560489     DOI: 10.1007/s13277-014-3007-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

1.  p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD.

Authors:  Sophie Cotteret; Zahara M Jaffer; Alexander Beeser; Jonathan Chernoff
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

Review 2.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

3.  Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.

Authors:  Olcun Umit Unal; Ahmet Ugur Yilmaz; Tugba Yavuzsen; Tulay Akman; Hulya Ellidokuz
Journal:  Asian Pac J Cancer Prev       Date:  2014

4.  Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor.

Authors:  Eyal Zcharia; Ruth Atzmon; Adi Nagler; Avichai Shimoni; Tamar Peretz; Israel Vlodavsky; Arnon Nagler
Journal:  Anticancer Drugs       Date:  2012-11       Impact factor: 2.248

5.  P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma.

Authors:  Zhe-ping Fang; Bei-ge Jiang; Xue-feng Gu; Bin Zhao; Rui-liang Ge; Fa-biao Zhang
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

Review 6.  CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

Authors:  Laurent Antoni; Nayanta Sodha; Ian Collins; Michelle D Garrett
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

7.  The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.

Authors:  Diyou Li; Xiaohong Yao; Ping Zhang
Journal:  Mol Cell Biochem       Date:  2013-07-23       Impact factor: 3.396

Review 8.  P21-activated kinase 4--not just one of the PAK.

Authors:  Anna E Dart; Claire M Wells
Journal:  Eur J Cell Biol       Date:  2013-04-04       Impact factor: 4.492

9.  P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration.

Authors:  Wei Gong; Zhengwen An; Yunling Wang; Xinyan Pan; Weigang Fang; Bo Jiang; Hongquan Zhang
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

10.  miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells.

Authors:  Jipeng Li; Yiping Wang; Yulan Song; Zhongming Fu; Wanjun Yu
Journal:  Mol Cancer       Date:  2014-08-16       Impact factor: 27.401

View more
  10 in total

Review 1.  Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.

Authors:  Yang-Guang Shao; Ke Ning; Feng Li
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 3.  Structure, biochemistry, and biology of PAK kinases.

Authors:  Rakesh Kumar; Rahul Sanawar; Xiaodong Li; Feng Li
Journal:  Gene       Date:  2016-12-19       Impact factor: 3.688

4.  Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma.

Authors:  Yinhe Sikong; Qing Wang; Meijuan Cai; Aijun Zhang; Fei Pang; Xiangdan Cui
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

5.  PAK5 facilitates the proliferation, invasion and migration in colorectal cancer cells.

Authors:  Silin Huang; Ying Zhu; Chunfei Wang; Xiaxi Li; Xiaobing Cui; Sufang Tu; Lijuan You; JingWen Fu; Zemin Chen; Wei Hu; Wei Gong
Journal:  Cancer Med       Date:  2020-05-08       Impact factor: 4.452

6.  P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer.

Authors:  Ding-Guo Zhang; Chan-Chan Gong; Xiao-Jin Wu; Xin Ren; Randee S Sedaka; Wei-Cong Chen; Fu-Chun Huo; Cheng Chen; Wen-Qi Du; Dong-Sheng Pei
Journal:  Signal Transduct Target Ther       Date:  2021-02-05

7.  PAK5 promotes the migration and invasion of cervical cancer cells by phosphorylating SATB1.

Authors:  Fu-Chun Huo; Yao-Jie Pan; Tong-Tong Li; Jie Mou; Dong-Sheng Pei
Journal:  Cell Death Differ       Date:  2018-08-06       Impact factor: 15.828

8.  MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5.

Authors:  Yao-Jie Pan; Lu-Lu Wei; Xiao-Jin Wu; Fu-Chun Huo; Jie Mou; Dong-Sheng Pei
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

9.  Activation of Mitochondrial 2-Oxoglutarate Dehydrogenase by Cocarboxylase in Human Lung Adenocarcinoma Cells A549 Is p53/p21-Dependent and Impairs Cellular Redox State, Mimicking the Cisplatin Action.

Authors:  Victoria I Bunik; Vasily A Aleshin; Xiaoshan Zhou; Vyacheslav Yu Tabakov; Anna Karlsson
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

10.  MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.

Authors:  Tong-Tong Li; Jie Mou; Yao-Jie Pan; Fu-Chun Huo; Wen-Qi Du; Jia Liang; Yang Wang; Lan-Sheng Zhang; Dong-Sheng Pei
Journal:  J Biomed Sci       Date:  2021-08-02       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.